|
Role of CpG Oligodeoxynucleotide (CpG-ODN) In Allergic Diseases
|
|
| Author:
|
UPLOADED BY-ADMIN, M. R. CHORAWALA, , P. M. OZA, S. S. DESHPANDE, G. B. SHAH
|
| Abstract:
|
Despite the advanced and increasing understanding of pathophysiology of asthma and other allergic disease, current
treatment remain unspecific and targets late events with the allergic cascade. Therefore, novel and promising approach is to
blunt the allergic inflammatory process through the administration of bacterial plasmid DNA. This review analyses the role
of CpG (cytosine-phosphorothioate-guanine) oligodeoxynucleotide (ODN) for the pathology of asthma, summarizes the
action, safety and efficacy of CpG-ODN therapy. The present review also gives rational approach for future indication and
direction of treatment with CpG oligodeoxynucleotide. Unmethylated cytosine-phosphorothioate-guanine
oligodeoxynucleotide (CpG-ODNs) exhibit potent immune-stimulant activity by binding with Toll-like receptor-9 (TLR-9)
expressed on antigen-presenting cells. It has been shown to activate B-cell, NK cell, macrophage and dendritic cell for
antigen specific T-cell response. CpG-ODN promotes Th2 mediated immune response occurring in asthma. This effect is
due to the induction of both IL-12 and interferon-? (IFN-gamma) which is also the presumptive mechanism of action of
conventional immunotherapy. The activation by CpG-ODN depends on sequence motifs containing the core dinucleotide
CpG since destruction of the motif strongly reduces immuno-stimulant potential.
|
| Keyword:
|
CpG, Oligodeoxynucleotide, allergic disease, Th1 and Th2 response
|
| EOI:
|
-
|
| DOI:
|
-
|
| Download:
|
Request For Article
|
|
|